TrialLancet (London, England)2026

Abluminus DES+ sirolimus-eluting stent versus everolimus-eluting stent in patients with diabetes and coronary artery disease (ABILITY Diabetes Global): results from a multicentre, randomised controlled trial.

Alexandre Abizaid et al.PubMed ↗Publisher ↗

No numbers read from the abstract.